These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
465 related articles for article (PubMed ID: 20940403)
1. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. Chock KL; Allison JM; Shimizu Y; ElShamy WM Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403 [TBL] [Abstract][Full Text] [Related]
2. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin. Paul BT; Blanchard Z; Ridgway M; ElShamy WM Oncogene; 2015 Jun; 34(23):3036-52. PubMed ID: 25132263 [TBL] [Abstract][Full Text] [Related]
3. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Blanchard Z; Paul BT; Craft B; ElShamy WM Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261 [TBL] [Abstract][Full Text] [Related]
4. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Yan X; Fraser M; Qiu Q; Tsang BK Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436 [TBL] [Abstract][Full Text] [Related]
5. 8‑bromo‑7‑methoxychrysin induces apoptosis by regulating Akt/FOXO3a pathway in cisplatin‑sensitive and resistant ovarian cancer cells. Ding Q; Chen Y; Zhang Q; Guo Y; Huang Z; Dai L; Cao S Mol Med Rep; 2015 Oct; 12(4):5100-8. PubMed ID: 26151347 [TBL] [Abstract][Full Text] [Related]
6. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Wu H; Cao Y; Weng D; Xing H; Song X; Zhou J; Xu G; Lu Y; Wang S; Ma D Cancer Lett; 2008 Nov; 271(2):260-71. PubMed ID: 18657898 [TBL] [Abstract][Full Text] [Related]
7. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Lee S; Choi EJ; Jin C; Kim DH Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433 [TBL] [Abstract][Full Text] [Related]
8. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Asselin E; Mills GB; Tsang BK Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739 [TBL] [Abstract][Full Text] [Related]
9. [Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms]. Wu HJ; Wu HT; Weng DH; Xing H; Lu YP; Ma D Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):612-6. PubMed ID: 17983517 [TBL] [Abstract][Full Text] [Related]
10. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway. Park J; Ko YS; Yoon J; Kim MA; Park JW; Kim WH; Choi Y; Kim JH; Cheon Y; Lee BL Gastric Cancer; 2014; 17(3):423-30. PubMed ID: 24202965 [TBL] [Abstract][Full Text] [Related]
11. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. Zhao Z; Wang J; Tang J; Liu X; Zhong Q; Wang F; Hu W; Yuan Z; Nie C; Wei Y Biochem J; 2012 Jun; 444(2):291-301. PubMed ID: 22394200 [TBL] [Abstract][Full Text] [Related]
12. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway. Zhang N; Qiu J; Zheng T; Zhang X; Hua K; Zhang Y Oncol Rep; 2018 Mar; 39(3):1034-1042. PubMed ID: 29286125 [TBL] [Abstract][Full Text] [Related]
13. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo. Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949 [TBL] [Abstract][Full Text] [Related]
14. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Fraser M; Bai T; Tsang BK Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180 [TBL] [Abstract][Full Text] [Related]
15. Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance. Singh M; Chaudhry P; Fabi F; Asselin E BMC Cancer; 2013 May; 13():233. PubMed ID: 23663432 [TBL] [Abstract][Full Text] [Related]
16. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer. Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223 [TBL] [Abstract][Full Text] [Related]
17. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin. Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609 [TBL] [Abstract][Full Text] [Related]
18. PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression. Wu H; Wang K; Liu W; Hao Q Biochem Biophys Res Commun; 2014 Feb; 444(2):141-6. PubMed ID: 24434152 [TBL] [Abstract][Full Text] [Related]
19. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway. Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells. Tsubaki M; Takeda T; Ogawa N; Sakamoto K; Shimaoka H; Fujita A; Itoh T; Imano M; Ishizaka T; Satou T; Nishida S Leuk Res; 2015 Apr; 39(4):445-52. PubMed ID: 25726084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]